Anne Wojcicki, CEO of 23andMe, spent a decade in healthcare and biotechnology before launching the DNA testing and analysis company in 2006. Her goal was twofold: to help individuals learn more about their own genetics, enabling them to pursue more personalized medical care, and to create a database of genetic information for commercial and academic researchers to promote broader improvements to the healthcare system. She speaks with HBR's Editor-in-Chief Adi Ignatius about tackling challenges in an emerging industry.
Fler avsnitt av HBR IdeaCast
Visa alla avsnitt av HBR IdeaCastHBR IdeaCast med Harvard Business Review finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
